NEW YORK (Legal Newsline) – The managers of the supply and distribution of Zantac and others are facing a class action lawsuit alleging they falsely marketed the over-the-counter drug as safe.
Edith Massiah, on behalf of herself and all others similarly situated, filed a complaint Dec. 31 in the U.S. District Court for the Southern District of New York against Sanofi-Aventis U.S. LLC, Sanofi U.S. Services Inc. and Chattem Inc., alleging unjust enrichment, fraudulent concealment and other claims.
The suit states Massiah purchased and took Zantac in September 2019 as well as on previous occasions. In September, the suit states the Food and Drug Administration issued a statement that N-nitrosodimethylamine (NDMA) was in certain medications and Zantac was on that list.
She alleges the defendants falsely marketed the over-the-counter drug as safe when the ranitidine-based Zantac contains "dangerously high levels" of N-nitrosodimethylamine (NDMA), which has been labeled a carcinogen by the World Health Organization and U.S. Environmental Protection Agency.
Massiah seeks compensatory and punitive damages, a trial by jury, interest and all other just relief. She is represented by Christopher Marlborough of The Marlborough Law Firm PC in Melville, New York.
U.S. District Court for the Southern District of New York case number 19-11944